Sp105
FIBROSIS IN EOE: CAN IT BE REVERSED? LESSONS LEARNED FROM IBD
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed. This session will examine all treatment options, review the importance of treat to target in EoE and examine if the endpoint of the disease, fibrosis can be reversed now or in the future. LIVE STREAM SESSION
The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed. This session will examine all treatment options, review the importance of treat to target in EoE and examine if the endpoint of the disease, fibrosis can be reversed now or in the future. LIVE STREAM SESSION
Presenter
The Children's Hospital of Philadelphia
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
FOXM1 REGULATES EPITHELIAL HOMEOSTASIS IN EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Enterochromaffin cells (ECs) are specialized gastrointestinal (GI) epithelial cells that transduce luminal forces and chemicals into release of signal molecules including serotonin (5-HT) to alter GI function including mucosal ion transport…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
